Plain-English translation of NCT04445909 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This trial is evaluating a new continuous monitoring device that measures carbon dioxide levels through the skin in patients receiving temporary heart support (called VA-ECMO). The researchers want to see if this non-invasive method works as well as traditional blood tests for tracking carbon dioxide and oxygen levels. This could help doctors manage patients on life support more safely and easily.
Patients on temporary heart-support machines need frequent blood tests to monitor their carbon dioxide and oxygen levels, which can be uncomfortable and time-consuming. A continuous skin-based monitoring method could allow doctors to track these levels without repeated needle sticks, making care safer and less burdensome.
You likely qualify if…
You likely don't qualify if…
If you are eligible, you would have the continuous carbon dioxide monitoring device placed on your skin while you are already receiving heart-support treatment. Over a four-hour period, the research team would take measurements from this device and compare them to traditional blood samples and other monitoring methods. Your doctors would also record information about your breathing machine settings, body temperature, and medications during this time.
AI-generated summary from trial data · Jun 17, 2026 · Not medical advice
Austria
Enrollment target
~30 participants
Started
November 2019
Primary completion
January 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 90 Years
Last updated on clinicaltrials.gov in December 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Martin Dworschak, MD, MBA
Medical University of Vienna
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.